Cargando…
Sunitinib re-challenge in advanced renal-cell carcinoma
Despite offering significant clinical benefits in advanced renal-cell carcinoma (RCC), the effectiveness of targeted therapies eventually declines with the development of resistance. Defining optimal sequences of therapy is therefore the focus of much current research. There is also evidence that tr...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453836/ https://www.ncbi.nlm.nih.gov/pubmed/24800947 http://dx.doi.org/10.1038/bjc.2014.214 |